Medicare, New Drugs, and a Surprising GLP-1 Trend, What Patients Need to Know
What happens when patients stop taking a GLP-1? New real-world data reveals that more than half eventually come back, and it may completely change the way we think about obesity treatment.In this week...
14 Heinä 31min
Compound GLP-1 Poll STUNS THE INTERNET!
What If We've Been Asking the Wrong Question?Patients say compounded GLP-1s are more effective than branded medications. Dave explains why the answer may have nothing to do with the drug itself, and e...
8 Heinä 15min
How To Get $50 GLP-1
Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode o...
23 Kesä 44min
What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs
ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen (@JcanNuSH) to break down the molecules, clinica...
16 Kesä 1h 15min
Retatrutide Just Reached Bariatric Surgery Results
Dave sits down with nurse practitioner and former Retatrutide clinical trial participant David White to break down the biggest obesity headlines from the 2026 American Diabetes Association Conference....
11 Kesä 48min
Retatrutide Before FDA Approval? Lilly Just Changed the Conversation
Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.
9 Kesä 20min
Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs
Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...
2 Kesä 20min
Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War
https://linktr.ee/manonthemounjaro
26 Touko 30min
